The emergence of compounds like copyright and Semaglutide signifies a significant shift in how we manage type 2 diabetes. These groundbreaking therapies belong to a class known as GLP-1 receptor agonists, which mimic the effects of a natural hormone that controls glucose levels and food intake. Originally, developed for diabetes, their effectivenes